A Phase II Trial of Carboplatin/Paclitaxel with and without Trastuzumab in HER2/neu+ Patients with Advanced orRecurrent Uterine Serous Papillary Cancer
What is the purpose of this trial?
To estimate whether the addition of trastuzumab to paclitaxel and carboplatin chemotherapy improves progression free survival (PFS) when compared to paclitaxel and carboplatin alone in USPC patients overexpressing HER2/neu at 3+ level by IHC or positive by FISH.
- Yale Cancer Center
- Last Updated:
- Study HIC#: